SEC Comment Letter for Brickell Biotech, Inc. (FRTX) (CIK 0000819050) — Feb 18, 2020
Brickell Biotech, Inc. (FRTX) (CIK 0000819050)
Date: Feb. 18, 2020 · CIK: 0000819050 · Accession: 0000000000-20-001495
AI Filing Summary & Sentiment
File numbers found in text: 333-236353
Letter
February 18, 2020 Robert B. Brown Chief Executive Officer Brickell Biotech, Inc. 5777 Central Avenue Suite 102 Boulder, CO 80301 Re:Brickell Biotech, Inc. Registration Statement on Form S-3 Filed February 10, 2020 File No. 333-236353 Dear Mr. Brown: We have limited our review of your registration statement to those issues we have addressed in our comment. Please respond to this letter by amending your registration statement and providing the requested information. If you do not believe our comment applies to your facts and circumstances or do not believe an amendment is appropriate, please tell us why in your response. After reviewing any amendment to your registration statement and the information you provide in response to the comment, we may have additional comments. Registration Statement on Form S-3 Information Incorporated by Reference, page 56 1.Please revise this section to incorporate the Quarterly Reports on Form 10-Q for the periods ended March 31, 2019 and June 30, 2019 and the Current Reports on Form 8-K filed on February 20, 2019 and May 24, 2019. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Refer to Rules 460 and 461 regarding requests for acceleration. Please allow adequate time for us to review any amendment prior to the requested effective date of the registration statement.
FirstName LastNameRobert B. Brown Comapany NameBrickell Biotech, Inc. February 18, 2020 Page 2 FirstName LastName Robert B. Brown Brickell Biotech, Inc. February 18, 2020 Page 2 You may contact Chris Edwards at (202) 551-6761 or Suzanne Hayes at (202) 551- 3675 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Anna T. Pinedo
Show Raw Text
February 18, 2020
Robert B. Brown
Chief Executive Officer
Brickell Biotech, Inc.
5777 Central Avenue
Suite 102
Boulder, CO 80301
Re:Brickell Biotech, Inc.
Registration Statement on Form S-3
Filed February 10, 2020
File No. 333-236353
Dear Mr. Brown:
We have limited our review of your registration statement to those issues we have
addressed in our comment.
Please respond to this letter by amending your registration statement and providing the
requested information. If you do not believe our comment applies to your facts and
circumstances or do not believe an amendment is appropriate, please tell us why in your
response.
After reviewing any amendment to your registration statement and the information you
provide in response to the comment, we may have additional comments.
Registration Statement on Form S-3
Information Incorporated by Reference, page 56
1.Please revise this section to incorporate the Quarterly Reports on Form 10-Q for the
periods ended March 31, 2019 and June 30, 2019 and the Current Reports on Form 8-K
filed on February 20, 2019 and May 24, 2019.
We remind you that the company and its management are responsible for the accuracy
and adequacy of their disclosures, notwithstanding any review, comments, action or absence of
action by the staff.
Refer to Rules 460 and 461 regarding requests for acceleration. Please allow adequate
time for us to review any amendment prior to the requested effective date of the registration
statement.
FirstName LastNameRobert B. Brown
Comapany NameBrickell Biotech, Inc.
February 18, 2020 Page 2
FirstName LastName
Robert B. Brown
Brickell Biotech, Inc.
February 18, 2020
Page 2
You may contact Chris Edwards at (202) 551-6761 or Suzanne Hayes at (202) 551-
3675 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Anna T. Pinedo